Welcome to Insider Healthcare. I’m healthcare editor Leah Rosenbaum, and today in healthcare news:
- Jack Stoddard, former executive of Haven and Accolade, has a new company for older adults;
- Stem cell manufacturing company Cellino is raising its next round of financing;
- The CDC isn’t stopping flights from the UK, despite a new COVID-19 variant.
A former Haven exec is working with Alphabet’s GV and Andreessen Horowitz to change how and where we care for older Americans
- Jack Stoddard, Haven’s former chief operating officer, is launching a new startup, Patina Health.
- It’s hoping to make healthcare easier for older people and their loved ones.
- Patina has raised $US57 ($AU76) million, and it’s launching early next year.
EXCLUSIVE: Rising biotech Cellino is raising $US75 ($AU100) million to make it easier to produce stem cells with AI
- Cellino is raising between $US75 ($AU100) million and $US80 ($AU107) million for a Series A round, sources told Insider.
- The startup is using artificial intelligence and lasers to develop treatments using stem cells.
- It launched in February with $US16 ($AU21) million in seed funding from Khosla Ventures and other investors.
The CDC has no plans to stop flights coming from the UK despite the rise of a new Delta-related variant
- About 6% of Delta cases in England are now of a variant called AY.4.2 – and the figure is rising.
- But the CDC has no plans to stop flights from the UK, its director Dr. Rochelle Walensky said.
- The CDC was “following the science very, very carefully,” she told NBC’s Meet The Press.
More stories we’re reading:
- I’m pregnant and got the COVID booster shot despite facing criticism from fellow moms – here’s how I made my decision (Insider)
- Not everyone agrees that COVID-19 vaccine boosters are needed for the general public (The New York Times)
- The US has a record number of sexually transmitted diseases and COVID-19 is making things worse, experts say (Insider)
- When public health experts decided to become less political, they led to the downfall of the field (The Atlantic)